RSS FLASCO

  • ASCO Special Series: Disparities in Cancer Care for Hispanic-LatinX People May 25, 2022
    EDITORIALS Disparities in Cancer Care and Scientific Knowledge in Hispanic/Latinx People in the United States Bosserman et al. pp. 367–369 Citation | Full Text | PDF (111 KB)  A Global Approach to Cancer Equity in the Hispanic/Latinx Population Green et al. pp. 371–373 Citation | Full Text | PDF (113 KB)  Challenges in Genetic Testing and Treatment Outcomes Among Hispanics With Lung Cancer...
  • Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials (Blood Advances 2022) April 13, 2022
  • Structural racism is a mediator of disparities in acute myeloid leukemia outcomes (Blood 20222) April 13, 2022
  • FDA approves alpelisib for PIK3CA-related overgrowth spectrum April 6, 2022
    On April 5, 2022, the Food and Drug Administration granted accelerated approval to alpelisib (Vijoice, Novartis Pharmaceuticals) for adult and pediatric patients two years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data from EPIK-P1 (NCT04285723), a single-arm clinical study in patients...
  • FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma April 1, 2022
    On April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma. Approval was...
  • FDA approves Pluvicto for metastatic castration-resistant prostate cancer March 25, 2022
    On March 23, 2022, the Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.  On the...
  • March is Myeloma Awareness Month March 22, 2022
    Racial disparity in myeloma has been evident in incidence and mortality with a twofold difference. Similarly, earlier age at diagnosis and monoclonal gammopathy are almost double in blacks compared to whites. The encouraging news is that outcomes can be similar if access and appropriate treatment specifically bortezomib and autologous transplant are utilized. There have been...
  • FDA approves Opdualag for unresectable or metastatic melanoma March 21, 2022
    On March 18, 2022, the Food and Drug Administration approved nivolumab and relatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab. Efficacy was evaluated in...
  • February is Black History Month February 9, 2022
    February is Black History Month started in 1926 conceived by historian Carter G Woodson  to honor African Americans and raise awareness of Black history.  Although many come to mind to honor, we highlight some pioneers to bring recognition.  Jane C Wright  was a pioneering cancer researcher and  the only woman among seven physicians who helped...
  • Living With Chronic Lymphocytic Leukemia (January 31, 2022) February 7, 2022